Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs

Executive Summary

Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies
Advertisement

Related Content

Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates
Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates
Remoxy Time-Release Oxycodone Phase III Trial Planned For Year-End
Solvay Cilansetron Irritable Bowel NDA Will Include “Appropriate Use Plan”
GSK Lotronex Risk Management Plan Should Not Be Altered, Cmte. Says
Novartis Revises Zelnorm Labeling With Diarrhea, Ischemic Colitis Risk Info
Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations
Glaxo Lotronex Withdrawal Follows Failed Risk Management Negotiations

Topics

Advertisement
UsernamePublicRestriction

Register

PS044295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel